Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Nov 14, 2018; 24(42): 4798-4808
Published online Nov 14, 2018. doi: 10.3748/wjg.v24.i42.4798
Table 3 Incidence and risk of end-stage renal disease in patients with Crohn’s disease and ulcerative colitis
Total No. (n)ESRD cases (n)Person-yearsESRD incidence (per 1000 person-years)Crude HR (95%CI)P valueModel 11 HR (95%CI)P valueModel 22 HR (95%CI)P valueModel 33 HR (95%CI)P value
Total CD< 0.001< 0.001< 0.001< 0.001
Non-CD control37755241849880.131 (reference)1 (reference)1 (reference)1 (reference)
CD cohort1258531611890.513.90 (2.29-6.65)4.00 (2.35-6.82)3.98 (2.31-6.85)6.33 (2.75-14.56)
CD subgroup< 0.001< 0.001< 0.001< 0.001
Non-CD control37755241849880.131 (reference)1 (reference)1 (reference)1 (reference)
Incident CD group558614218360.644.92 (2.53-9.57)5.18 (2.66-10.07)4.21 (2.12-8.35)6.30 (2.56-15.26)
Prevalent CD group699917393530.433.34 (1.79-6.23)3.37(1.81-6.29)3.81(2.03-7.16)6.38 (2.47-16.47)
Total UC0.9410.9610.3070.089
Non-UC control786811423835870.371 (reference)1 (reference)1 (reference)1 (reference)
UC cohort26227481280560.371.01 (0.73-1.40)1.01 (0.73-1.40)1.22 (0.88-1.70)2.01 (0.90-4.51)
UC subgroup0.8210.8210.5130.235
Non-UC control786811423835870.371 (reference)1 (reference)1 (reference)1 (reference)
Incident UC group1102018438100.411.14 (0.70-1.87)1.27 (0.77-2.08)1.19 (0.73-1.96)1.99 (0.83-4.80)
Prevalent UC group1520730842470.360.95 (0.64-1.41)0.90 (0.61-1.33)1.24 (0.83-1.84)2.03 (0.87-4.72)